Business
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
LEXINGTON, Mass., May 04, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/022427699151300f30c58fada4123c1b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xFScskMOP68bIWtskXkSJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMA--/https://media.zenfs.com/en/business-wire.com/022427699151300f30c58fada4123c1b","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/K3lNIa4Nmciu84wInlA17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA-/https://media.zenfs.com/en/business-wire.com/022427699151300f30c58fada4123c1b","width":1200,"height":250}},"lazy":false},{"type":"text","content":"LEXINGTON, Mass., May 04, 2026--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.","length":262,"tagName":"p"},{"type":"text","content":"Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program.","length":253,"tagName":"p"},{"type":"text","content":"About Agenus","length":12,"tagName":"p"},{"type":"text","content":"Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.","length":782,"tagName":"p"},{"type":"text","content":"About Botensilimab (BOT)","length":24,"tagName":"p"},{"type":"text","content":"Botensilimab (BOT) is a human Fc en...